STAT3 and cancer: Despite not yet being used in clinical practice, several STAT3 inhibitors have demonstrated a reduction of malignant phenotypes in different cancer types [28, 29, 30, 31], with AZD9150 and TTI‐101 (formerly C188‐9) showing promising therapeutic efficacy in clinical trials [32, 33, 34, 35].